Trial watch toll-like receptor agonists for cancer therapy

Erika Vacchelli, Alexander Eggermont, Catherine Sautès-Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

143 Citaten (Scopus)

Samenvatting

Toll-like receptors (TLRs) have long been known for their ability to initiate innate immune responses upon exposure to conserved microbial components such as lipopolysaccharide (LPS) and double-stranded RNA. More recently, this family of pattern recognition receptors has been attributed a criticalrole in the elicitation of anticancer immune responses, raising interest in the development of immunochemotherapeutic regimens based on natural or synthetic TLR agonists. In spite of such an intense wave of preclinical and clinical investigation, only three TLR agonists are currently licensed by FDA for use in cancer patients: bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovisthat operates as a mixed TLR2/ TLR4 agonist; monophosphoryl lipid A (MPL), a derivative of Salmonellaminnesota that functions as a potent agonist of TLR4; and imiquimod, a synthetic imidazoquinoline that activates TLR7. One year ago, in the August and September issues of OncoImmunology, we described the main biological features of TLRs and discussed the progress of clinical studies evaluating the safety and therapeutic potential of TLR agonists in cancer patients. Here, we summarize the latest developments in this exciting area of research, focusing on preclinical studies that have been published during the last 13 mo and clinical trials launched in the same period to investigate the antineoplasticactivity of TLR agonists

Originele taal-2Engels
Artikelnummere25238
TijdschriftOncoImmunology
Volume2
Nummer van het tijdschrift8
DOI's
StatusGepubliceerd - 2013
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Trial watch toll-like receptor agonists for cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit